A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea. by 이순민
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
A 6-year safety surveillance of 10-valent
pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) in
South Korea
Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon Hyung Kim,
Rupert W. Jakes, Raghavendra Devadiga & Moon Sung Park
To cite this article: Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon
Hyung Kim, Rupert W. Jakes, Raghavendra Devadiga & Moon Sung Park (2018): A 6-year
safety surveillance of 10-valent pneumococcal non-typeable Haemophilus￿influenzae protein D
conjugate vaccine (PHiD-CV) in South Korea, Human Vaccines & Immunotherapeutics, DOI:
10.1080/21645515.2018.1502525
To link to this article:  https://doi.org/10.1080/21645515.2018.1502525
© 2018 GSK group of companies. Published
with license by Taylor & Francis Group, LLC
Accepted author version posted online: 07
Aug 2018.
Published online: 29 Aug 2018.




A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
Soon Min Lee a, Jang Hoon Lee b, Eun Song Song c, Sung Jin Kimd, Joon Hyung Kim d, Rupert W. Jakese,
Raghavendra Devadigaf, and Moon Sung Park b
aDepartment of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; bDepartment of Pediatrics, Ajou
University School of Medicine, Suwon, Korea; cDepartment of Pediatrics, Chonnam National University Medical School, Gwangju, Korea; dGSK, Seoul,
Korea; eGSK, Singapore, Singapore; fGSK, Bangalore, India
ABSTRACT
In 2010, Korea introduced 10-valent pneumococcal conjugate vaccine for children aged 6 weeks to
5 years against invasive disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14,
18C, 19F, 23F and cross-reactive 19A. The aim of this 6-year real-world study of 646 healthy Korean
children from 16 centers vaccinated in routine practice is to monitor vaccine safety, as per Ministry of
Food and Drug Safety regulations. Around 50% had a past or existing medical condition, 19.3% an
existing condition and 7.6% received concomitant medication). Total of 489 recorded adverse events
(AEs) were reported in 274 infants; 86% were mild and the rest moderate, only three were reported as
serious. Most AEs (97.8%) were not related to vaccination; one case of injection-site swelling and of fever
was related, two cases of fever were probably related, five cases of fever and one case each of diarrhea
and coughing were possibly related. None of the serious AEs were related to vaccination. Of 11 adverse
drug reactions (ADRs) in 10 subjects, none were serious. Overall, 263 subjects (40.7%) received medica-
tion (mainly antibiotics or antipyretics) for the treatment of an AE, of which 6 subjects were treated for
an ADR. There was no difference in the incidence of AEs according to age, sex or concomitant
vaccination. Subjects with an existing medical condition had significantly more AEs than those without
any conditions (p = 0.03), but no differences regarding ADRs. Four-dose vaccination with PHiD-CV
appears to have a clinically-acceptable safety profile for Korean children.
ClinicalTrials.gov identifier: NCT01248988
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Pneumococcal disease, caused by Streptococcus pneumoniae
(S. pneumoniae) spreads by droplets of respiratory secretions1
and can cause different types of illnesses, including meningi-
tis, sepsis, pneumonia, and otitis media.2 Severe pneumococ-
cal disease accounts for around 14.5 million cases globally
each year among children under five years old,3 resulting in
almost 500,000 deaths, mostly in developing countries.4
Routine pneumococcal conjugate vaccination programs for
infants have dramatically decreased invasive pneumococcal
disease incidence, with near elimination of disease caused by
vaccine serotypes in some places.5
The pneumococcus comprises over 90 serotypes,4 each
producing a unique polysaccharide, called the capsule, which
is a major virulence factor and the target of pneumococcal
conjugate vaccines.6 Two pneumococcal conjugate vaccines
have market authorization; Prevenar (also Prevnar, PCV13,
Pfizer) is a 13-valent vaccine conjugated to CRM197 protein,
and Synflorix (GSK) is a 10-valent vaccine using protein D,
derived from non-typeable Haemophilus influenzae, as a
carrier protein for 8 out of the 10 serotypes.
The 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV, Synflorix,
GSK) containing pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V,
14, 18C, 19F and 23F was registered in Korea in March
2010.7 The vaccine is indicated for active immunization of
infants and children from 6 weeks up to 5 years of age
against invasive disease, pneumonia and acute otitis media
caused by S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14,
18C, 19F, and 23F.8 In May 2016, the European Medicines
Agency updated the label to include effectiveness for cross-
reactive serotype 19A invasive pneumococcal disease (IPD),
based on three postmarketing observational studies
conducted in Brazil, Finland, and Canada (Quebec).8,9
A matched case-control study in Brazil10, reported a signifi-
cant decrease in IPD due to any vaccine serotype, and 19A
serotype (i.e., adjusted effectiveness 82.2% (95% confidence
interval [CI] 10.7, 96.4)).10,11 In Finland12, a comparison of
before and after introducing the vaccine into the national
immunization program found a significant decrease of 80%
(95% CI 72, 85) in the incidence of any culture-confirmed
IPD, including IPD due to serotype 19A.11,12 In Quebec13, a
decrease of incidence in vaccine serotype IPD as well as in
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serotype 19A IPD was observed, showing 71% (95% CI
24, 89) vaccine effectiveness.11,13
Following registration, Korea’s Ministry of Food and
Drug Safety (MFDS) requires postmarketing surveillance
(PMS) to collect safety information in at least 600 Korean
infants and children over a 6-year period.14,15 Therefore the
aim of this 6-year PMS study was to monitor the safety of
PHiD-CV vaccination given according to Korean Prescribing
Information (PI) in routine practice.16
Results
Participants
Subjects were recruited from 16 centers in Korea including
university hospitals, general hospitals, women’s hospitals and
paediatric hospitals/clinics. A total of 647 subjects were enrolled,
of which 646 subjects were included in the safety analysis. One
subject was excluded as the age of this subject was not within
the protocol-defined range (i.e. primary vaccination at 2, 4 and
6 months of age, six weeks to five years old at first dose).
The majority of subjects enrolled in the study when receiving
their first dose (519 subjects, 80.3%), 43 subjects (6.7%) enrolled
when receiving their second dose, 54 subjects (8.4%) enrolled
when receiving their third dose and 30 subjects (4.6%) enrolled
when receiving their booster dose. As a result, among the 646
subjects enrolled; 519 subjects received dose one, 466 subjects
received dose two (includes subjects who enrolled when receiving
doses one and two), 399 subjects received dose three (includes
subjects who enrolled when receiving doses one, two or three)
and 57 subjects received a booster dose (includes subjects who
enrolled when receiving doses one, two, three or booster).
Descriptive data
All subjects were of Korean heritage, 52.2% were male. The
mean age of subjects at dose 1 was 11.7 weeks (Standard
deviation [SD] 9.7 weeks), at dose 2 was 20.7 weeks (SD
7.9 weeks), at dose 3 was 29.7 weeks (SD 5.4 weeks) and for
the booster dose was 61.4 weeks (SD 6.6 weeks).
Overall, 302 subjects (46.7%) had a past medical condition;
mainly respiratory, thoracic and mediastinal disorders (20.7%,
e.g., upper respiratory infection), skin and subcutaneous tissue
(12.2%, e.g. atopic or seborrheic dermatitis), hepatobiliary (10.1%,
e.g., neonatal jaundice) or gastrointestinal disorders (7.1%, e.g.,
acute gastroenteritis), and 21 were premature babies. Of the 646
subjects, 125 (19.3%) had an existing medical condition; mainly
respiratory, thoracic andmediastinal disorders (6.7%, e.g., asthma
or upper respiratory infection) or skin and subcutaneous tissue
disorders (4.6%, e.g., atopic dermatitis or miliaria).
During the entire study period, 312 subjects (48.3%)
received concomitant medication; out of these, 49 were not
treated for AE. Overall, 134 (20.7%) subjects received anti-
biotics and 97 (15.0%) received antipyretics. The majority of
subjects on concomitant medication reported using respira-
tory medication (246, 38.1%), alimentary tract and metabo-
lism medication (183, 28.3%) and anti-infectives (140, 21.7%).
The percentage of subjects receiving concomitant medication
by visit was; 28.5% following dose one, 29.4% following dose
two, 30.6% following dose three and 36.8% following the boos-
ter dose visit. The majority of subjects (630 subjects [97.5%])
received concomitant vaccinations most frequently including;
Haemophilus influenzae b vaccine (609 subjects), rotavirus vac-
cine (434 subjects), hepatitis B vaccine (189 subjects) and
diphtheria tetanus and acellular pertussis vaccine (179 subjects).
Safety data
A total of 489 adverse events (AEs) were reported by 274 subjects
(42.4%) and 11 adverse drug reactions (ADRs) were reported by
10 subjects (1.6%) during the study period. Three subjects (0.5%)
reported three serious adverse events (SAEs) (i.e., erythema mul-
tiforme, urinary tract infection and pneumonia), which were
assessed by investigators as unlikely to be related to PHiD-CV
vaccination. There were no serious ADRs reported (Table 1).
When assessing the occurrence of events after each dose,
post-dose one; one subject reported an SAE, 114 subjects
(22.0%) reported AEs, and seven subjects reported eight
ADRs. Post-dose two; two subjects reported two SAEs, 119
subjects (25.5%) reported AEs, and, two subjects reported two
ADRs. Post-dose three; 99 subjects (24.8%) reported AEs, and
one subject had an ADR. Following the booster dose; 16
subjects (28.1%) reported AEs.
Most AEs (422) and one ADR (i.e., coughing) were con-
sidered unexpected (i.e. not in the PI). The most frequently
reported unexpected AEs were respiratory disorders in 34.5%
of subjects (95% Confidence Interval [CI] 30.9, 38.3); 327
cases in 223 subjects, and gastrointestinal disorders in 4.8%
of subjects (95% CI 3.3, 6.7); 32 cases in 21 subjects. Only 1
unexpected case (i.e., coughing) was considered possibly
related to vaccination. See Table 2 for details of the most
frequent unexpected AEs reported in over 10 cases.
Among the three subjects with an SAE; pneumonia lasting
29 days, and erythema multiforme lasting nine days, were
reported five and 11 days respectively after receiving dose two
of PHiD-CV. Urinary tract infection, lasting four days, was
reported seven days after dose one of PHiD-CV. All of the
SAEs were assessed by the investigators as unlikely to be related
to PHiD-CV vaccination, and, all resolved by the end of the study.
Among the 489 AEs, 419 (85.7%) were graded as mild in
intensity and 67 (13.7%) were graded as moderate in intensity
Table 1. Summary of events over the study period (Total vaccinated
cohort = 646).
AE characteristics n* (AEs) n (subjects) % (subjects)
AE total 489 274 42.41
Unexpected AE 422 251 38.85
Mild 419 242£ 37.46£
Moderate 67 50£ 7.74£
Severe 0 0 0.00
SAE total 3 3 0.46
Unexpected SAE 3 3 0.46
ADR total 11 10 1.55
Unexpected ADR 1 1 0.15
SADR total 0 0 0.00
Unexpected SADR 0 0 0.00
£Same subjects can be included under both Mild and Moderate. Severity is not
captured for 3 AEs whose details are missing.
ADR: adverse drug reaction; AE: adverse event; n*: number of events; n: number
of subjects with at least one symptom; SADR: serious adverse drug reaction;
SAE: serious adverse event
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by investigators. There were no severe-intensity AEs
(Table 1). The most frequent moderate AEs (≥ 5 cases)
were; 11/96 cases (11.5%) of upper respiratory tract infection,
5/16 cases (31.3%) of gastroenteritis, 18/44 cases (40.9%) of
bronchitis, and, 8/40 cases (20.0%) of bronchiolitis.
Investigators assessed whether AEs were caused by vacci-
nation as follows, according to MFDS requirements. Most of
the AEs (478, 97.8%) reported during the entire study period
were assessed as unlikely to be related to vaccination. Of the
11 ADRs; two cases each (0.4%) were certainly and probably
related to vaccination, and, seven cases (1.4%) were possibly
related to vaccination. There were no AEs with causality
classed as conditional or as unassessable/unclassifiable.
Vaccination was certain to have caused a case of injection
site swelling and of fever, probably caused two cases of fever,
and possibly caused five cases of fever and one case each of
diarrhea and coughing. See full details in Appendix Table 1.
Influencing factors for AEs and ADRs
There was no significant difference in outcomes stratified by
gender (p = 0.74 for AEs, p = 0.10 for ADRs); by age < 1 year
old versus ≥ 1 year old (p = 0.65 for AEs, no ADRs in ≥ 1 year
olds), for those with or without a previous medical condition
(p = 0.35 for AEs, p = 0.09 for ADRs), or, by concomitant
vaccination (p = 0.53). Subjects with a current medical con-
dition had significantly more AEs than subjects without it
(51.2% vs 40.3%, p = 0.03) although with no significant
difference for ADRs). As most medication use in the study
was related to AEs (i.e., 263/312 subjects with medication use
was for AE/ADRs), those on medication were much more
likely to have had an AE than those with no medication use
(86.2% versus 1.5%, p < 0.0001) (Table 3).
As for the duration of AEs, 38.5% (n = 179) lasted for
4–7 days; the most frequent types of AE in this category
were 31.3% (n = 30/96) of upper respiratory tract infec-
tions, 44.4% (n = 24/54) of nasopharyngitis cases, 41.9%
(n = 18/44) of bronchitis cases, 28.2% (n = 11/40) of
bronchiolitis cases, 37% (n = 10/27) of respiratory disor-
ders, and 50% (n = 11/22) of diarrhea cases (Figure 1). The
AEs that lasted for over 30 days (n = 11, 2.4%) included;
one case each of upper respiratory tract infection, rhinitis,
respiratory disorder, pneumonia, nasopharyngitis, fracture,
contact dermatitis, atopic dermatitis, and, three cases of
bronchitis. All reported AEs had resolved by the end of
the study, except for 4 cases (bronchitis, atopic dermatitis,
otitis media and rhinorrhea) for which the outcome was
unknown.
Discussion
The results of this study showed that four-dose vaccination
with PHiD-CV was well tolerated in Korean infants. A total of
646 subjects from 16 hospitals in Korea were included in the
safety analysis over a 6-year period and have particular impor-
tance in that they covered different levels of medical and
regional support. Data from around two-thirds (≥ 399) of
subjects were analysed for each primary vaccine dose, and
from 57 subjects for the booster dose. Almost all subjects
received other vaccinations during the study period, as
expected. The similar safety and reactogenicity profiles of
PHiD-CV were confirmed when administered for primary
and booster vaccination of children from 6 countries, using
a range of vaccination schedules and coadministered with
other routinely used pediatric vaccines. As this was a real-
world study, around 19% of subjects had an existing condi-
tion, around 8% were receiving other medication and 21
premature babies were included in the study.












Bronchiolitis 40 34 5.3% Unlikely
Bronchitis 44 37 5.7% Unlikely
Coughing 11 11 1.7% 1 Possibly
10 Unlikely
Nasopharyngitis 54 43 6.7% Unlikely
Respiratory disorder 27 16 2.5% Unlikely
Rhinitis 10 10 1.5% Unlikely
Rhinorrhea 12 11 1.7% Unlikely
Upper respiratory tract
infection
96 81 12.5% Unlikely
Gastrointestinal disorders
Gastroenteritis 16 16 2.5% Unlikely
Resistance mechanism disorders
Otitis media 21 17 2.6% Unlikely
Vision disorders
Conjunctivitis 10 10 1.5% Unlikely
AE: adverse event; n*: number of events; n: number of subjects with at least one
symptom; Possibly: temporal sequence of the administration and use of PHiD-
CV appropriate but it could also be explained by other medications, chemical
substances or concomitant disease; Unlikely: transitory case which may not
have had causality with the administration and use of PHiD-CV, also explained
reasonably by other medications, chemical substances or latent disease.













Male N = 337 238 145 0.743 3 3 0.097
Female N = 309 251 129 8 7
Age
< 1 year old
N = 605
465 258 0.650 11 10 -
≥ 1 year old
N = 41
24 16 - -
Previous medical condition
Yes N = 302 253 134 0.346 8 7 0.088
No N = 344 236 140 3 3
Existing medical condition
Yes N = 125 117 64 0.027 4 4 0.080
No N = 521 372 210 7 6
Concomitant medication (for treatment of AEs or other)
Yes N = 312 482 269 < 0.0001 8 7 0.101
No N = 334 7 5 3 3
Medication used for AE treatment
Yes N = 263 472 263 < 0.0001 7 6 0.118
No N = 383 17 11 4 4
Concomitant antibiotics
Yes N = 134 271 131 < 0.0001 2 2 0.304
No N = 512 218 143 9 8
Concomitant antipyretics
Yes N = 97 179 85 < 0.0001 3 3 0.130
No N = 549 310 189 8 7
Concomitant vaccination
Yes N = 630 475 266 0.534 11 10 -
No N = 16 14 8 - -
ADR: adverse drug reaction; AE: adverse event; N: number of vaccinated subjects;
n*: number of events; n = number of subjects with at least one symptom
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A total of 489 AEs were recorded in 274 subjects; 97.5% were
not considered to be related to vaccination. Most of them were
infectious events including respiratory, gastrointestinal and other
systems’ disorders considered as existing infections or conditions
related to an underlying disease by the study investigators. Most
AEs (85.7%) were graded as mild, and the rest as moderate in
intensity. Vaccination with PHiD-CV caused one case of injec-
tion-site swelling and of fever, probably caused two cases of fever,
and possibly caused five cases of fever and one each of diarrhea
and coughing. There were three SAEs(i.e., erythema multiforme,
urinary tract infection and pneumonia), but none were assessed as
related to vaccination by the study investigators after the exam-
ination of the patients. There were 11 ADRs recorded in 10
subjects, none of which were serious ADRs. The incidence is
relatively low compared to previous reports. In other studies,
overall, SAEs were reported by 150 of 2,996 subjects (5%).
Redness was the most commonly reported solicited local symp-
tom. Pain or swelling at the injection site were the most com-
monly reported grade 3 local symptoms.17 As for the reports from
the European Union Summary of Product Characteristics (EU
SPC), following administration of PHiD-CV in the primary infant
vaccination series, the most frequently reported AEs were irrit-
ability (55% of all doses), and redness at the injection site (41% of
all doses). Irritability (53%) and pain at the injection site (51%)
were the most common AEs after the booster dose.8 These AEs
were transient and mild to moderate in severity in most cases.
There was also no increase in the frequency or severity of these
events with subsequent doses of PHiD-CV during primary
vaccination.17 According to the recommendation from EU SPC,
the use of prophylactic antipyretics is recommended when PHiD-
CV is given concomitantly with vaccines containing whole cell
pertussis, and in children with seizure disorders or with a prior
history of febrile seizures.8 During this entire study period, 97
(15.0%) received antipyretics. No significant differences were
found by gender, age, concomitant vaccinations, or for past med-
ical conditions in terms of risk of developing an AE, however,
significantly more subjects with an existing medical condition
reported AEs compared with those without any condition. Care
should be taken when administering PHiD-CV to infants with
comorbidities.
The results of this study were as expected, with no safety
signals detected for rare or serious ADRs, and comparable to
the safety findings of clinical trials of PHiD-CV.8,11 Safety
results were also comparable to those seen in a phase III
randomized clinical trial of PHiD-CV co-administered with
the diphtheria, tetanus, acellular pertussis, hepatitis B virus,
inactivated poliovirus and Haemophilus influenzae type b
vaccine (DTPa-HBV-IPV/HiB) in Vietnamese infants; i.e.,
pain at injection site, irritability and fever were the most
common local and general AEs, respectively, seen in the
PHiD-CV group, with no SAEs causally related to the
vaccine.18
PHiD-CV was proven to be well tolerated and generally as
immunogenic in preterm infants as in term infants when
given as a 3-dose primary vaccination followed by a booster
dose. Incidences of fever and other solicited general symp-
toms were generally similar. Irritability was the most fre-
quently reported solicited general AE for preterm infants
after primary vaccination and the booster dose while upper
respiratory tract infections were some of the most frequently
reported unsolicited AEs.19
There were some limitations to this study. As this was an
observational public health surveillance study, there was no
randomization, blinding or control group.
A relatively small number of hospitals were included. A
small number of subjects enrolled in the study after
already receiving their first, second or third primary vac-
cination, therefore safety data following those vaccinations
were not available. The number of subjects who received a
booster dose was relatively small compared to those vacci-
nated with the primary series. Data were self-reported,






































Duration of AEs (Days)
Number of AEs
Figure 1. Duration of adverse events (days) (Total vaccinated cohort = 646).
AE: adverse event
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proportion reporting a reaction was consistent with data
from previous years. Despite the short timeframe for self-
reporting of AEs after each dose, it is possible that incom-
plete information about medication or AEs was provided
by parents/guardians. Some of the subjects included had
existing conditions (mostly respiratory, thoracic or med-
iastinal disorders) for which it was not possible to deter-
mine the severity of illness, and some subjects were
receiving concomitant medication other than for AEs. It
was not possible to state whether these factors may have
influenced the vaccination outcomes. Results should there-
fore be interpreted with caution and more data are needed
in the future to confirm the safety outcomes observed for
this group in this study.
Conclusions
In conclusion, based on six years of safety data collected from
16 centers, four-dose vaccination with PHiD-CV appears to




A 6-year prospective, non-comparative, observational PMS
study was conducted in 16 centers in Korea to actively
collect data on the frequency and severity of adverse events
(AEs) and serious adverse events (SAEs), following vaccina-
tion with PHiD-CV given in routine practice and according
to Korean Prescribing Information (NCT01248988).
Setting and population
Subjects attending a participating center for vaccination
were enrolled if their parents/guardians gave consent and
if they met the following inclusion and exclusion criteria.
Subjects were included if; they received ≥ 1 dose of PHiD-
CV as part of routine practice at a hospital or private clinic,
were aged six weeks to five years old at first dose, and, their
parent/guardian was likely to comply (according to the
investigator) with completion of the diary cards. Subjects
were excluded if; at the time of study entry they had any
contraindication indicated in the local Prescribing
Information, they had received any investigational or non-
registered pneumococcal vaccine thirty days prior to the
study start, or they had received a pneumococcal vaccine
other than PHiD-CV. Informed consent was obtained from
the parent/guardian of the child.
Subject numbers were assigned sequentially from a range
of numbers allocated to each center.
Ethics
The study was conducted in accordance with local regulatory
requirements (MFDS). Parents/guardians of subjects provided
written informed consent for the collection and handling of
personal and safety information before conducting any study-
specific procedures.
Vaccination
Routine infant vaccination consisted of a three-dose primary
vaccination series given at two, four and six months of age,
followed by a booster dose at least six months after the last
dose, preferably between 12–15 months of age. The same
primary series and booster dose are recommended for pre-
term infants (27–36 week gestation). For older infants
(> 7 months of age) and children up to five years old who
were not previously vaccinated, the schedule consisted of a
two-dose primary vaccination series, two months apart, fol-
lowed by a booster dose in infants aged under 12 months of
age.16
Outcomes and measurements
Demographic data such as age, gender and race were
recorded as well as any pre-existing conditions or signs
and symptoms present prior to the start of the study. A
history-directed medical examination and a physical exam-
ination of the subject was conducted. Treatment of any
abnormality observed during this examination was per-
formed according to local medical practice or by referral
to an appropriate health care provider. Information regard-
ing all vaccines administered since birth was collected. At
each subsequent study visit, investigators recorded any con-
comitant medication, given during a 30-day period follow-
ing administration of each dose. Concomitant medication
could include any medication administered prophylactically
in anticipation of a reaction to vaccination as well as any
medication intended to treat an AE.
The oral, axillary, tympanic or rectal body temperature
of subjects was measured prior to vaccination. Visits were
rescheduled for subjects with fever (i.e., oral, axillary or
tympanic temperature ≥ 37.5°C (99.5°F), or rectal tem-
perature ≥ 38.0°C (100.4°F) or any clinical condition not
suitable for vaccination. After completing any prerequisite
procedures prior to vaccination, one dose of PHiD-CV
was administered according to the PI (i.e., given by intra-
muscular injection, at the preferred sites of the anterolat-
eral aspect of the thigh in infants or the deltoid muscle of
the upper arm in young children). Vaccinees were closely
monitored for ≥ 30 minutes in case of anaphylaxis.
Following vaccination and for a period of 30 days after
each dose, the occurrence of any AEs was recorded by the
parent/guardian in a diary card to be returned to the investi-
gator at the next visit or by phone or mail. Subjects were
followed until resolution of the AE. Any signs or symptoms
perceived as serious were reported immediately to investiga-
tors. Investigators verified and discussed the recorded safety
information against source documents and with the parent/
guardian. The investigators then differentiated between
expected AEs (i.e., reported in the PI) and unexpected AEs,
for the 30-day follow-up period after each dose, and, recorded
SAEs using the latest version of Korea’s PMS SAE Reporting
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Form, from the first dose in the study up to 30 days after the
last dose.
Definition and assessment of AEs, ADRs and SAEs
An AE was defined as any untoward medical occurrence,
temporally associated with the use of a medicinal product,
whether or not considered related to the medicinal product.
Symptoms were coded using the World Health
Organization Adverse Reactions Terminology (WHO-ART
092 version); AEs mentioned in the PI were classed as
‘expected’, while all others were classed as ‘unexpected’.20
AEs possibly due to vaccination (so-called adverse drug
reactions, ADR) were any AE with causality graded as
“certainly” or “probably/likely” or “possibly” related to vac-
cination, or AEs that were “conditional/unclassified” or
“unassessible/unclassifiable”. ADRs were also classed as
expected or unexpected according to the events mentioned
in the PI. A SAE was defined as any untoward medical
occurrence that; resulted in death, was life-threatening,
required hospitalization or prolongation of existing hospi-
talization, or resulted in disability or incapacity. An SADR
was an SAE for which causality was classed as “certainly” or
“probably/likely” or “possibly” related to vaccination, or
SAEs that were “conditional/unclassified” or “unassessible/
unclassifiable”.
Investigators assessed the intensity and causality of AEs
and SAEs using their clinical judgement. Regarding causality,
the most frequent unexpected AEs were mostly graded as
‘Unlikely’ to be related to vaccination (e.g., transitory AE
which may not have had causality with the administration
and use of PHiD-CV, or which can also be reasonably
explained by other medications, chemical substances or latent
disease), and one AE was graded as ‘Possibly’ related to
vaccination (i.e., temporal sequence of the administration
and use of PHiD-CV is appropriate but the AE could also
be explained by other medications, chemical substances or
concomitant disease). The maximum intensity over the dura-
tion of each event was classified as mild, moderate or severe.
Mild events were; easily tolerated by the subject, caused mini-
mal discomfort and did not interfere with everyday activities.
Mild fever was 37.5°C to 38.0°C. Moderate events were suffi-
ciently discomforting to interfere with normal everyday activ-
ities. Moderate fever was > 38°C to 39.0°C. Severe events
prevented normal, everyday activities. Severe fever was
> 39.0°C. The relationship between vaccination and the occur-
rence of AEs or SAEs was investigated, considering plausible
alternative causes, the natural history of underlying diseases,
concomitant therapy and other risk factors. A distinction was
made between non-serious and serious AEs; for SAEs,
additional
examinations and tests were performed to determine all
possible contributing factors such as medical history, other
medication or procedures, lack of efficacy of the vaccine(s), if
applicable, erroneous administration and any other causes. As
per the requirements of Korea’s MFDS, causality was classi-
fied on a six-point scale; from 1) Certain to 2) Probable/Likely
to 3) Possible to 4) Unlikely to 5) Conditional/unclassified to 6)
Unassessable/unclassifiable.20
Statistical methods
Descriptive demographic characteristics of the study cohort
were tabulated. Mean ages in weeks of subjects receiving
each primary vaccination dose and booster dose were
computed.
The safety analyses were conducted on the total vaccinated
cohort. The AEs/SAEs were analyzed by their expected or unex-
pected status. Numbers of subjects by types of AEs were tabulated.
The number and the percentage of any AE occurring within
30 days of each dose were tabulated; for each dose, for overall
doses and per subject. The same calculations were done for any
AEs according to severity and for those assessed as causally
related to vaccination. The number and percentage of subjects
with concomitant medication (and of doses of concomitant med-
ication) were tabulated, after each vaccine dose and overall. SAEs
and withdrawals due to AEs were described in detail.
Factors such as age, gender, existing medical conditions,
concomitant medications, concomitant vaccination, and dura-
tion of follow-up were considered as factors that could affect
AE outcomes. Results were stratified, using the Chi-squared
test for significant differences (p values) for AEs and the
Fisher’s Exact test for ADRs.
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